BRPI1007018A2 - composto, composição farmacêutica, e , uso de um composto. - Google Patents

composto, composição farmacêutica, e , uso de um composto.

Info

Publication number: BRPI1007018A2
Authority: BR; Brazil
Prior art keywords: compound; pharmaceutical composition; pharmaceutical; composition
Prior art date: 2009-01-26

Application number

BRPI1007018A

Other languages

English (en)

Inventor

Stanislas Mayer

Stephan Schann

Original Assignee

Domain Therapeutics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-26

Filing date

2010-01-25

Publication date

2016-03-29

2010-01-25 Application filed by Domain Therapeutics filed Critical Domain Therapeutics

2016-03-29 Publication of BRPI1007018A2 publication Critical patent/BRPI1007018A2/pt

2020-03-10 Publication of BRPI1007018B1 publication Critical patent/BRPI1007018B1/pt

2021-05-25 Publication of BRPI1007018B8 publication Critical patent/BRPI1007018B8/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Gastroenterology & Hepatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

BRPI1007018A 2009-01-26 2010-01-25 composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto. BRPI1007018B8 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP20090360007 EP2210891A1 (en)	2009-01-26	2009-01-26	New adenosine receptor ligands and uses thereof
EP09360007.0		2009-01-26
PCT/IB2010/000416 WO2010084425A1 (en)	2009-01-26	2010-01-25	New adenosine receptor ligands and uses thereof

Publications (3)

Publication Number	Publication Date
BRPI1007018A2 true BRPI1007018A2 (pt)	2016-03-29
BRPI1007018B1 BRPI1007018B1 (pt)	2020-03-10
BRPI1007018B8 BRPI1007018B8 (pt)	2021-05-25

Family

ID=40669959

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1007018A BRPI1007018B8 (pt)	2009-01-26	2010-01-25	composto ligante de receptores de adenosina, composição farmacêutica, e, uso de um composto.

Country Status (15)

Country	Link
US (1)	US9029393B2 (pt)
EP (2)	EP2210891A1 (pt)
JP (2)	JP5680553B2 (pt)
CN (1)	CN102365280B (pt)
AU (1)	AU2010207494B2 (pt)
BR (1)	BRPI1007018B8 (pt)
CA (1)	CA2750449C (pt)
CY (1)	CY1114329T1 (pt)
DK (1)	DK2391625T3 (pt)
ES (1)	ES2419280T3 (pt)
IL (1)	IL214167A (pt)
NZ (1)	NZ594405A (pt)
PT (1)	PT2391625E (pt)
WO (1)	WO2010084425A1 (pt)
ZA (1)	ZA201105791B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2210891A1 (en) *	2009-01-26	2010-07-28	Domain Therapeutics	New adenosine receptor ligands and uses thereof
JP5641664B2 (ja)	2009-10-30	2014-12-17	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用
AR080754A1 (es)	2010-03-09	2012-05-09	Janssen Pharmaceutica Nv	Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP2013538798A (ja) *	2010-08-03	2013-10-17	グラフィニティファーマシューティカルズゲーエムベーハー	アフィニティクロマトグラフィーによる抗体およびＦｃ融合タンパク質精製のためのリガンド
US9238643B2 (en)	2010-09-06	2016-01-19	Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Sciences	Amide compounds
BR112013033375B1 (pt)	2011-06-27	2022-05-10	Janssen Pharmaceutica N.V	Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
US8883819B2 (en)	2011-09-01	2014-11-11	Irm Llc	Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
EP2751107A1 (en) *	2011-09-01	2014-07-09	Irm Llc	Compounds and compositions as pdgfr kinase inhibitors
US9745339B2 (en)	2012-02-08	2017-08-29	Novalix Deutschland Gmbh	Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV
AU2013283426B2 (en)	2012-06-26	2018-02-22	Janssen Pharmaceutica Nv	Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
WO2014009305A1 (en)	2012-07-09	2014-01-16	Janssen Pharmaceutica Nv	Inhibitors of phosphodiesterase 10 enzyme
WO2014101120A1 (en)	2012-12-28	2014-07-03	Merck Sharp & Dohme Corp.	Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
JO3544B1 (ar) *	2015-03-19	2020-07-05	Kyowa Kirin Co Ltd	عامل علاجي للاختلال الوظيفي في الفص الجبهي
RU2019117556A (ru) *	2016-11-18	2020-12-18	Мерк Шарп И Доум Корп.	Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2
CN110612100B (zh) *	2017-05-05	2023-04-14	艾库斯生物科学有限公司	治疗与癌症有关疾病的喹唑啉-吡啶衍生物
CN110785187B (zh)	2017-06-22	2024-04-05	诺华股份有限公司	针对cd73的抗体分子及其用途
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Antibody molecules to cd73 and uses thereof
MX2020004756A (es)	2017-11-16	2020-08-20	Novartis Ag	Terapias de combinacion.
CA3083949A1 (en)	2017-11-30	2020-06-06	Novartis Ag	Bcma-targeting chimeric antigen receptor, and uses thereof
US20190292188A1 (en)	2018-02-27	2019-09-26	Incyte Corporation	Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
BR122022000386B1 (pt)	2018-03-14	2022-09-27	Surface Oncology, Inc	Anticorpos que se ligam a cd39, composição farmacêutica e kit dos mesmos
MA52940A (fr)	2018-05-18	2021-04-28	Incyte Corp	Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
JP7158500B2 (ja)	2018-05-22	2022-10-21	ザリバーカンパニーインコーポレイテッド	スルフィニルアミノベンズアミドおよびスルホニルアミノベンズアミド誘導体
TWI869346B (zh)	2018-05-30	2025-01-11	瑞士商諾華公司	Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
KR20250151605A (ko)	2018-06-01	2025-10-21	노파르티스 아게	Bcma에 대한 결합 분자 및 이의 용도
TWI748194B (zh)	2018-06-28	2021-12-01	德商菲尼克斯Ｆｘｒ有限責任公司	含有雙環核心部分之新穎lxr調節劑
CN113166153B (zh)	2018-07-05	2024-11-01	因赛特公司	作为a2a/a2b抑制剂的稠合吡嗪衍生物
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3117512A1 (en)	2018-10-25	2020-04-30	Merck Patent Gmbh	5-azaindazole derivatives as adenosine receptor antagonists
KR20210083287A (ko)	2018-10-25	2021-07-06	메르크 파텐트 게엠베하	아데노신 수용체 안타고니스트로서의 5-아자인다졸 유도체
MX2021007392A (es)	2018-12-20	2021-08-24	Novartis Ag	Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
US12577217B2 (en)	2019-01-08	2026-03-17	Kyorin Pharmaceutical Co., Ltd.	15-PGDH inhibitor
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
JP7532385B2 (ja) *	2019-01-31	2024-08-13	杏林製薬株式会社	１５－ｐｇｄｈ阻害薬
IL285315B2 (en)	2019-02-07	2025-12-01	Beigene Ltd	Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
WO2020165834A1 (en)	2019-02-15	2020-08-20	Novartis Ag	Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
BR112021015783A2 (pt)	2019-02-15	2021-10-05	Novartis Ag	Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos
TW202124444A (zh)	2019-09-16	2021-07-01	美商表面腫瘤學公司	抗ｃｄ３９抗體組合物及方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en)	2019-09-18	2021-03-25	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
AU2020353672A1 (en)	2019-09-25	2022-03-31	Surface Oncology, LLC	Anti-IL-27 antibodies and uses thereof
TW202135859A (zh)	2019-12-20	2021-10-01	瑞士商諾華公司	組合療法
WO2021260528A1 (en)	2020-06-23	2021-12-30	Novartis Ag	Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7819176B2 (ja)	2020-08-03	2026-02-24	ノバルティスアーゲー	ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
US12029718B2 (en)	2021-11-09	2024-07-09	Cct Sciences, Llc	Process for production of essentially pure delta-9-tetrahydrocannabinol
IL302569A (en)	2020-11-06	2023-07-01	Novartis Ag	Cd19 binding molecules and uses thereof
EP4255904A2 (en) *	2020-12-03	2023-10-11	Domain Therapeutics	Novel par-2 inhibitors
GB202019622D0 (en) *	2020-12-11	2021-01-27	Adorx Therapeutics Ltd	Antagonist compounds
JP2024505049A (ja)	2021-01-29	2024-02-02	ノバルティスアーゲー	抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
CN115093372B (zh) *	2022-06-16	2023-05-30	安徽工程大学	一种咪唑衍生物的合成方法
CN120677155A (zh) *	2022-12-07	2025-09-19	第三谐波生物股份有限公司	作为c-Kit激酶抑制剂的化合物和组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2764387B1 (fr)	1997-06-05	1999-07-23	Centre Nat Rech Scient	Utilisation d'une proteine fluorescente pour la detection d'interactions entre une proteine cible et son ligand
JP2003525291A (ja) *	2000-03-01	2003-08-26	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	２，４−二置換チアゾリル誘導体
CA2484631A1 (en) *	2002-05-13	2003-11-27	Merck & Co., Inc.	Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
US7186832B2 (en) *	2003-02-20	2007-03-06	Sugen Inc.	Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP2392565B1 (en) *	2003-09-26	2014-03-19	Exelixis, Inc.	c-Met modulators and methods of use
JP2005126374A (ja) *	2003-10-24	2005-05-19	Kissei Pharmaceut Co Ltd	新規なアデノシンａ２ａ受容体拮抗剤
TW200524887A (en) *	2003-10-27	2005-08-01	Lundbeck & Co As H	N-thiazol-2-yl-benzamide derivatives
WO2006068954A2 (en) *	2004-12-21	2006-06-29	Schering Corporation	PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS
US7557103B2 (en) *	2005-04-05	2009-07-07	Eli Lilly And Company	Imidazopyridazine compounds
US7754717B2 (en) *	2005-08-15	2010-07-13	Amgen Inc.	Bis-aryl amide compounds and methods of use
DE102005042742A1 (de) *	2005-09-02	2007-03-08	Schering Ag	Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
WO2009060197A1 (en) *	2007-11-08	2009-05-14	Centro Nacional De Investigaciones Oncologicas (Cnio)	Imidazopyridazines for use as protein kinase inhibitors
WO2009100375A1 (en) *	2008-02-06	2009-08-13	Bristol-Myers Squibb Company	Substituted imidazopyridazines useful as kinase inhibitors
EP2210891A1 (en) *	2009-01-26	2010-07-28	Domain Therapeutics	New adenosine receptor ligands and uses thereof
WO2010111060A1 (en) *	2009-03-23	2010-09-30	Merck Sharp & Dohme Corp.	P2x3, receptor antagonists for treatment of pain
EP2751107A1 (en) *	2011-09-01	2014-07-09	Irm Llc	Compounds and compositions as pdgfr kinase inhibitors
US8969565B2 (en) *	2012-03-09	2015-03-03	Lexicon Pharmaceuticals, Inc.	Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use

2009
- 2009-01-26 EP EP20090360007 patent/EP2210891A1/en not_active Withdrawn
2010
- 2010-01-25 JP JP2011546998A patent/JP5680553B2/ja not_active Expired - Fee Related
- 2010-01-25 BR BRPI1007018A patent/BRPI1007018B8/pt not_active IP Right Cessation
- 2010-01-25 NZ NZ59440510A patent/NZ594405A/xx not_active IP Right Cessation
- 2010-01-25 CN CN201080013843.5A patent/CN102365280B/zh not_active Expired - Fee Related
- 2010-01-25 US US13/146,327 patent/US9029393B2/en active Active
- 2010-01-25 EP EP20100708373 patent/EP2391625B1/en active Active
- 2010-01-25 AU AU2010207494A patent/AU2010207494B2/en not_active Ceased
- 2010-01-25 ES ES10708373T patent/ES2419280T3/es active Active
- 2010-01-25 WO PCT/IB2010/000416 patent/WO2010084425A1/en not_active Ceased
- 2010-01-25 DK DK10708373T patent/DK2391625T3/da active
- 2010-01-25 CA CA2750449A patent/CA2750449C/en active Active
- 2010-01-25 PT PT107083735T patent/PT2391625E/pt unknown
2011
- 2011-07-19 IL IL214167A patent/IL214167A/en active IP Right Grant
- 2011-08-05 ZA ZA2011/05791A patent/ZA201105791B/en unknown
2013
- 2013-06-19 CY CY20131100498T patent/CY1114329T1/el unknown
2015
- 2015-01-06 JP JP2015000660A patent/JP6201098B2/ja active Active

Also Published As

Publication number	Publication date
PT2391625E (pt)	2013-07-05
EP2210891A1 (en)	2010-07-28
EP2391625A1 (en)	2011-12-07
HK1167392A1 (en)	2012-11-30
CN102365280A (zh)	2012-02-29
US20110288074A1 (en)	2011-11-24
US9029393B2 (en)	2015-05-12
AU2010207494B2 (en)	2015-12-03
CY1114329T1 (el)	2016-08-31
CN102365280B (zh)	2014-10-29
JP2012515759A (ja)	2012-07-12
IL214167A0 (en)	2011-08-31
CA2750449C (en)	2018-03-13
DK2391625T3 (da)	2013-07-01
AU2010207494A1 (en)	2011-08-25
WO2010084425A1 (en)	2010-07-29
JP2015110599A (ja)	2015-06-18
EP2391625B1 (en)	2013-05-01
BRPI1007018B1 (pt)	2020-03-10
ES2419280T3 (es)	2013-08-20
BRPI1007018B8 (pt)	2021-05-25
IL214167A (en)	2017-09-28
NZ594405A (en)	2013-09-27
ZA201105791B (en)	2014-01-29
CA2750449A1 (en)	2010-07-29
JP6201098B2 (ja)	2017-09-27
JP5680553B2 (ja)	2015-03-04

Legal Events

Date	Code	Title	Description
2017-08-01	B25A	Requested transfer of rights approved	Owner name: KALDI PHARMA (FR)
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-04-09	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-08-27	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2020-01-28	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-03-10	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/03/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/01/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2025-11-25	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.

Publication	Publication Date	Title
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BRPI1016219A2 (pt)	2016-04-26	composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt)	2016-03-08	composto, uso de um composto, e, composição farmacêutica
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BRPI0815709A2 (pt)	2017-06-13	composro, composição farmacêutica, e, uso de um composto.
BRPI1009757A2 (pt)	2016-03-15	composto, composição farmacêutica, e , uso de um composto.
BR112013008259A2 (pt)	2017-12-12	composto, composição farmacêutica, e, uso de um composto
BRPI1008498A2 (pt)	2015-08-25	Composto, prodroga do composto, medicamento, e, uso de um composto.
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
BR112013015397A2 (pt)	2016-09-20	composto, composição farmacêutica, e, uso de um composto
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BRPI0917579A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos, e, uso de um composto
BRPI1012892A2 (pt)	2018-03-13	composto, e, composição farmacêutica.
BRPI0810161A2 (pt)	2014-12-30	Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto
BRPI0915134A2 (pt)	2016-02-16	composto, e, uso de um composto
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
BR112012031226A2 (pt)	2018-03-06	composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0915473A2 (pt)	2015-11-10	composto, composição farmacêutica, e, uso de um composto
BRPI0812942A2 (pt)	2014-12-16	Composto, composição farmacêutica e uso de um composto
BRPI0810019A2 (pt)	2014-10-14	Composto, composição farmacêutica, e, uso de um composto
BRPI1007017A2 (pt)	2016-03-29	uso de um composto.